The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer
Zhiyao Fan,1–4,* Kun Fan,1–4,* Yitao Gong,1–4,* Qiuyi Huang,1–4 Chao Yang,1–4 He Cheng,1–4 Kaizhou Jin,1–4 Quanxing Ni,1–4 Xianjun Yu,1–4 Guopei Luo,1–4 Chen Liu1–4 1Department of Pancreatic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-crpalbumin-ratio-predicts-survival-and-monitors-chemotherapeutic-e-peer-reviewed-article-CMAR |
| _version_ | 1818912900896522240 |
|---|---|
| author | Fan Z Fan K Gong Y Huang Q Yang C Cheng H Jin K Ni Q Yu X Luo G Liu C |
| author_facet | Fan Z Fan K Gong Y Huang Q Yang C Cheng H Jin K Ni Q Yu X Luo G Liu C |
| author_sort | Fan Z |
| collection | DOAJ |
| description | Zhiyao Fan,1–4,* Kun Fan,1–4,* Yitao Gong,1–4,* Qiuyi Huang,1–4 Chao Yang,1–4 He Cheng,1–4 Kaizhou Jin,1–4 Quanxing Ni,1–4 Xianjun Yu,1–4 Guopei Luo,1–4 Chen Liu1–4 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China; 4Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Guopei Luo; Chen LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, People’s Republic of ChinaTel +86-21-6403-1446Fax +86-21-6403-1446Email luoguopei@fudanpci.org; liuchen@fudanpci.orgPurpose: The CRP/albumin (Alb) ratio, a recently reported predictor, has shown value for prognosis in various human cancers. This study aimed to determine the prognostic value of baseline CRP/Alb and to explore the relevance between postchemotherapy CRP/Alb and the efficacy of chemotherapy in advanced pancreatic cancer patients.Patients and methods: Five hundred and ninety-five patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas were enrolled. Cut-off Finder was used to calculate the best cut‑off value for baseline CRP/Alb. The primary endpoint was overall survival, which was analyzed by Kaplan-Meier survival curves with 95% confidence intervals. The log rank test and Cox proportional hazard model were used to evaluate the univariate and multivariate analyses.Results: The optimal cut-off value for baseline CRP/Alb was determined to be 0.18. Both the baseline CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, hazard ratio [HR] = 2.506; p<0.001) and postchemotherapy CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, HR = 1.854; p =0.002) were significant predictors of overall survival according to multivariate analysis and were independent of other factors. Patients with a baseline and postchemotherapy CRP/Alb ≥0.18 had the worst prognosis.Conclusion: CRP/Alb is a strong and useful indicator of prognosis for advanced pancreatic cancer. Both baseline and postchemotherapy CRP/Alb can be used in predicting the survival of patients and monitoring the effectiveness of chemotherapy in clinical practice.Keywords: CRP/Alb ratio, pancreatic cancer, prognosis, chemotherapy |
| first_indexed | 2024-12-19T23:21:57Z |
| format | Article |
| id | doaj.art-25b6d5cc783e4edaa5ed7576c0219704 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-19T23:21:57Z |
| publishDate | 2019-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-25b6d5cc783e4edaa5ed7576c02197042022-12-21T20:01:56ZengDove Medical PressCancer Management and Research1179-13222019-09-01Volume 118781878848871The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic CancerFan ZFan KGong YHuang QYang CCheng HJin KNi QYu XLuo GLiu CZhiyao Fan,1–4,* Kun Fan,1–4,* Yitao Gong,1–4,* Qiuyi Huang,1–4 Chao Yang,1–4 He Cheng,1–4 Kaizhou Jin,1–4 Quanxing Ni,1–4 Xianjun Yu,1–4 Guopei Luo,1–4 Chen Liu1–4 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Shanghai Pancreatic Cancer Institute, Shanghai, People’s Republic of China; 4Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Guopei Luo; Chen LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, People’s Republic of ChinaTel +86-21-6403-1446Fax +86-21-6403-1446Email luoguopei@fudanpci.org; liuchen@fudanpci.orgPurpose: The CRP/albumin (Alb) ratio, a recently reported predictor, has shown value for prognosis in various human cancers. This study aimed to determine the prognostic value of baseline CRP/Alb and to explore the relevance between postchemotherapy CRP/Alb and the efficacy of chemotherapy in advanced pancreatic cancer patients.Patients and methods: Five hundred and ninety-five patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas were enrolled. Cut-off Finder was used to calculate the best cut‑off value for baseline CRP/Alb. The primary endpoint was overall survival, which was analyzed by Kaplan-Meier survival curves with 95% confidence intervals. The log rank test and Cox proportional hazard model were used to evaluate the univariate and multivariate analyses.Results: The optimal cut-off value for baseline CRP/Alb was determined to be 0.18. Both the baseline CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, hazard ratio [HR] = 2.506; p<0.001) and postchemotherapy CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, HR = 1.854; p =0.002) were significant predictors of overall survival according to multivariate analysis and were independent of other factors. Patients with a baseline and postchemotherapy CRP/Alb ≥0.18 had the worst prognosis.Conclusion: CRP/Alb is a strong and useful indicator of prognosis for advanced pancreatic cancer. Both baseline and postchemotherapy CRP/Alb can be used in predicting the survival of patients and monitoring the effectiveness of chemotherapy in clinical practice.Keywords: CRP/Alb ratio, pancreatic cancer, prognosis, chemotherapyhttps://www.dovepress.com/the-crpalbumin-ratio-predicts-survival-and-monitors-chemotherapeutic-e-peer-reviewed-article-CMARCRP/Alb ratiopancreatic cancerprognosischemotherapy. |
| spellingShingle | Fan Z Fan K Gong Y Huang Q Yang C Cheng H Jin K Ni Q Yu X Luo G Liu C The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer Cancer Management and Research CRP/Alb ratio pancreatic cancer prognosis chemotherapy. |
| title | The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer |
| title_full | The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer |
| title_fullStr | The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer |
| title_full_unstemmed | The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer |
| title_short | The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer |
| title_sort | crp albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer |
| topic | CRP/Alb ratio pancreatic cancer prognosis chemotherapy. |
| url | https://www.dovepress.com/the-crpalbumin-ratio-predicts-survival-and-monitors-chemotherapeutic-e-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT fanz thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT fank thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT gongy thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT huangq thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT yangc thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT chengh thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT jink thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT niq thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT yux thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT luog thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT liuc thecrpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT fanz crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT fank crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT gongy crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT huangq crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT yangc crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT chengh crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT jink crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT niq crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT yux crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT luog crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer AT liuc crpalbuminratiopredictssurvivalandmonitorschemotherapeuticeffectivenessinpatientswithadvancedpancreaticcancer |